Recent Updates
Recently added Catalysts
IBRX Positive Sentiment

ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer

Wednesday, October 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: ImmunityBio announced the completion of the database lock for Cohort A of its QUILT-2.005 trial. This registrational trial assesses ANKTIVA® combined with BCG against BCG alone in BCG-naïve non-muscle invasive bladder cancer (NMIBC) patients. The treatment is delivered directly into the bladder without chemotherapy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Database lock completed for QUILT-2.005 trial.
  • ANKTIVA® shows promise as a chemotherapy-free option.
  • Trial evaluates combination therapy in NMIBC patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+49%
120-day peak, hindsight
Typical move
5.8%
average across 4 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
Nogapendekin alfa inbakicept
NDA/BLA · NSCLC Stage IV

Full Press Release Details

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced completion of the database lock for Cohort A of QUILT-2.005 (NCT02138734), its randomized, controlled, registrational trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) versus BCG alone in patients with BCG-naïve NMIBC. The chemotherapy-free combination is delivered directly into the bladder. The database lock follows the

Frequently Asked Questions

What is the QUILT-2.005 trial?

The QUILT-2.005 trial evaluates ANKTIVA® with BCG versus BCG alone.

What does database lock mean?

Database lock indicates that data collection for the trial is complete.

What is ANKTIVA® used for?

ANKTIVA® is being tested for treating non-muscle invasive bladder cancer.

Is ANKTIVA® chemotherapy-free?

Yes, ANKTIVA® is delivered without chemotherapy in this trial.

ShareAdd on Google
Tags: IBRX ImmunityBio ANKTIVA BCG NMIBC clinical trial
Last updated: Oct 21, 2026

Biotech snapshot

Cash runway
$357M liquidity · $22M/mo burn
~14 mo
Low dilution risk
Lead asset
Nogapendekin alfa inbakiceptNDA/BLA
NSCLC Stage IV →

Catalyst track record

+49%
best trade around IBRX's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for IBRX.

See every catalyst's timing & PoA →